Related references
Note: Only part of the references are listed.Neuroprotective Multifunctional Iron Chelators: From Redox-Sensitive Process to Novel Therapeutic Opportunities
Orly Weinreb et al.
ANTIOXIDANTS & REDOX SIGNALING (2010)
Biological metals and Alzheimer's disease: Implications for therapeutics and diagnostics
James A. Duce et al.
PROGRESS IN NEUROBIOLOGY (2010)
Role of iron in neurotoxicity: a cause for concern in the elderly?
James M. Stankiewicz et al.
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE (2009)
Neuro-inflammation induced in the hippocampus of 'binge drinking' rats may be mediated by elevated extracellular glutamate content
Roberta J. Ward et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Intranasal Deferoxamine Provides Increased Brain Exposure and Significant Protection in Rat Ischemic Stroke
Leah R. Hanson et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Deferoxamine Mesylate A New Hope for Intracerebral Hemorrhage: From Bench to Clinical Trials
Magdy Selim
STROKE (2009)
Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation
Or Kakhlon et al.
BLOOD (2008)
Validation of a robust and sensitive method for detecting hydroxyl radical formation together with evoked neurotransmitter release in brain microdialysis
Wolfhardt Freinbichler et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Oxidative stress hypothesis in Alzheimer's disease: a reappraisal
Domenico Pratico
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo
Anthony C. Vernon et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Selective iron chelation in Friedreich ataxia:: biologic and clinical implications
Nathalie Boddaert et al.
BLOOD (2007)
Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia
Maria Domenica Cappellini et al.
CLINICAL THERAPEUTICS (2007)
Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease
Yael Avramovich-Tirosh et al.
JOURNAL OF NEUROCHEMISTRY (2007)
6-Hydroxydopamine-induced alterations in blood-brain barrier permeability
PM Carvey et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2005)
The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease
KP Datla et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2004)
Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats
D Ben Shachar et al.
NEUROPHARMACOLOGY (2004)
Role of free radicals in the neurodegenerative diseases - Therapeutic implications for antioxidant treatment
B Halliwell
DRUGS & AGING (2001)
Share Paper
